期刊
NATURE REVIEWS CANCER
卷 10, 期 11, 页码 775-783出版社
NATURE PORTFOLIO
DOI: 10.1038/nrc2943
关键词
-
类别
资金
- Ligue Nationale contre le Cancer, France
- Institut Universitaire de France, France
- Institut National du Cancer, France
- European Economic community, National High Tech Program for Biotechnology of China, the Chinese National Key Basic Research Project, China
- National Natural Science Foundation of China, the Key Discipline Program of Shanghai Municipal Education Commission, China
The fusion oncogene, promyelocytic leukaemia (PML)-retinoic acid receptor-alpha (RARA), initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and increased self-renewal of leukaemic progenitor cells. The current standard of care is retinoic acid (RA) and chemotherapy, but arsenic trioxide also cures many patients with APL, and an RA plus arsenic trioxide combination cures most patients. This Review discusses the recent evidence that reveals surprising new insights into how RA and arsenic trioxide cure this leukaemia, by targeting PML-RAR alpha for degradation. Drug-triggered oncoprotein degradation may be a strategy that is applicable to many cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据